The aim of this retrospective study was to investigate the significance of newly defined micro-T790M mutation in 1G, 2G, and 3G EGFR-TKI efficacy using the large EGFR mutation-positive NSCLC cohort. This evidence concerns the gene EGFR and non-small cell lung carcinoma.